Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T, et al. Barbash GI, et al. Among authors: diaz r. Circulation. 1993 Jan;87(1):53-8. doi: 10.1161/01.cir.87.1.53. Circulation. 1993. PMID: 8419024
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study.
White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, Heikkilä J, Kristinsson A, Moulopoulos S, Paolasso EA, et al. White HD, et al. Among authors: diaz r. Circulation. 1993 Nov;88(5 Pt 1):2097-103. doi: 10.1161/01.cir.88.5.2097. Circulation. 1993. PMID: 8222103
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T, et al. Barbash GI, et al. Among authors: diaz r. Arch Intern Med. 1994 Oct 10;154(19):2237-42. Arch Intern Med. 1994. PMID: 7944845 Clinical Trial.
2,370 results